Morgan Stanley sets AUD 200.00 target for CSL stock

Published on 10/19/2026 at 09:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morgan Stanley set an AUD 200.00 target on October 18, 2026. CSL stock traded at EUR 118.93 on October 19, 2026, with AUD 93.1 billion market value.

Targets and corporate milestones

Morgan Stanley set an AUD 200.00 target for CSL on October 18, 2026.
CSL announced an Alentis partnership with an initial USD 355 million payment on October 5, 2026.
CSL stock traded at EUR 118.93 at 9:06 a.m. CEST at Lang & Schwarz on October 19, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL (ISIN AU000000CSL8) was trading at EUR 118.93 in the German market on October 19, 2026, while Morgan Stanley set an AUD 200.00 target for the Australian biotechnology company on October 18, 2026. The new target gives investors a fresh valuation reference after a difficult earnings reset.

According to TradingView on October 18, 2026, Morgan Stanley set the AUD 200.00 price target. TipRanks reported on October 19, 2026 that Morgan Stanley maintained a Buy rating alongside the target.

What does AUD 200.00 signal?

The target sits alongside CSL's latest annual reset. Fiscal year 2026 revenue reached USD 15.8 billion, up 1.5 percent from fiscal year 2025, while the company reported a USD 2.58 billion net loss after impairment and restructuring charges, according to Simply Wall St. The contrast explains why the analyst target depends heavily on recovery in the underlying operations rather than on the latest statutory earnings.

Three dated CSL milestones

On August 31, 2026, CSL announced a USD 1.5 billion plan to expand U.S. manufacturing, according to its CSL newsroom. On October 5, 2026, CSL announced a partnership with Alentis that included a USD 355 million initial payment and up to USD 1.2 billion in commercial milestones. On October 18, 2026, Morgan Stanley set the AUD 200.00 target.

Which date comes next?

CSL's next substantiated corporate date is its annual general meeting on October 27, 2026, in Melbourne, as listed by Simply Wall St.

Valuation meets execution

The market is weighing a higher analyst target against the scale of CSL's restructuring and investment program. CSL's market capitalization was AUD 93.1 billion on October 19, 2026, and its ASX 52-week range was AUD 90.00 to AUD 221.76. The company remains a global biopharmaceutical group with operations spanning plasma therapies and vaccines.

CSL stock was trading at EUR 118.93 at Lang & Schwarz on October 19, 2026 at 9:06 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of CSL stock.